The burgeoning field of metabolic disease management is witnessing a remarkable convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://getsocialpr.com/story23469146/retatrutide-and-nmn-a-integrated-system-to-metabolic-condition